VOR Schedule 13D/A: 1,374,775 Shares Held After Market Sales

Rhea-AI Filing Summary

Amendment No. 6 to Schedule 13D reports that Reprogrammed Interchange LLC and Reid Hoffman jointly beneficially own 1,374,775 shares of Vor Biopharma Inc., representing 20.1% of the common stock. The filing discloses open-market sales by Reprogrammed Interchange LLC from August 25, 2025 through October 9, 2025, including two recent sales of 75,262 shares on October 8, 2025 at a weighted average price of $33.8651 and 48,884 shares on October 9, 2025 at $32.068. A sequence of prior sales is listed with dates, share amounts and weighted average prices; all share figures reflect the 1-for-20 reverse stock split effected on September 18, 2025. No new agreements, litigation disclosures or changes to voting/dispositive power beyond the reported sales are stated.

Positive

• Reporting persons still hold a substantial 20.1% stake (1,374,775 shares), maintaining significant influence
• Sales disclosed were executed in open market transactions, with no contracts or new arrangements affecting securities reported

Negative

• Series of open-market sales reduced the holding by more than 1% over the reported days, increasing free float
• Recent weighted average sale prices declined$33.8651 on October 8, 2025 to $32.068 on October 9, 2025

Insights

Equity Investor Relations Analyst

Stake trimmed to 20.1% after multiple open-market sales.

The reporting persons now beneficially own 1,374,775 shares, equal to 20.1% of the class. The schedule lists a concentrated series of sales from August 25, 2025 through October 9, 2025, with recent trades on October 8, 2025 and October 9, 2025 at weighted average prices of $33.8651 and $32.068, respectively.

These dispositions reduced the stake by more than one percent over two days, which may affect short-term free float and voting dynamics; monitor any further Schedule 13D/A updates within the next 30 days for additional sales or intent changes.

Corporate Governance Specialist

Significant holder remains a large shareholder with shared voting/dispositive power.

The cover page shows shared voting power and shared dispositive power of 1,374,775 shares for both reporting persons, and no sole voting or dispositive power. Item 6 reports no contracts or arrangements affecting securities.

Because no new agreements or contested governance actions are disclosed, governance risks tied to these filings are limited to the mechanical effects of reduced ownership; watch for any future statements clarifying intent or changes to voting arrangements over the next quarter.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)

VOR BIOPHARMA INC.

(Name of Issuer)

Common Stock, par value $.0001 per share

(Title of Class of Securities)

929033108

(CUSIP Number)

Frank Huang, Manager
101 Mission Street, Suite 1000,
San Francisco, CA, 94105
(415) 541-0200

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/08/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 929033108

1

Name of reporting person

Reprogrammed Interchange LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,374,775.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,374,775.00

11

Aggregate amount beneficially owned by each reporting person

1,374,775.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

20.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 929033108

1

Name of reporting person

Reid Hoffman

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

AF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 1,374,775.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 1,374,775.00

11

Aggregate amount beneficially owned by each reporting person

1,374,775.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

20.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $.0001 per share
(b)	Name of Issuer: VOR BIOPHARMA INC.
(c)	Address of Issuer's Principal Executive Offices: 100 Cambridgepark Drive, Suite 101, Cambridge, MASSACHUSETTS , 02140.
Item 1 Comment: This Amendment No. 6 to Schedule 13D amends and supplements the information provided in the previously filed Statement on Schedule 13D filed with the Securities and Exchange Commission on January 7, 2025 and in Amendment No. 1, Amendment No. 2, Amendment No. 3, Amendment No. 4 and Amendment No. 5 thereto filed with the Securities and Exchange Commission on August 29, 2025, September 9, 2025, September 12, 2025, October 6, 2025 and October 8, 2025, respectively (collectively, the "Schedule 13D"), jointly on behalf of Reprogrammed Interchange LLC and Reid Hoffman (each a "Reporting Person" and collectively, the "Reporting Persons"). Except as supplemented herein, such statements, as heretofore amended and supplemented, remain unchanged in all material respects and in full force and effect. Capitalized terms used but not defined herein have the meaning ascribed to such term in the Schedule 13D, as amended. Responses to each item of this Amendment No. 6 to Schedule 13D are incorporated by reference into the response to each other item, as applicable.
Item 3.	Source and Amount of Funds or Other Consideration
	Not applicable.
Item 4.	Purpose of Transaction
	Item 4 of Schedule 13D is hereby amended and supplemented as follows: From October 8, 2025 through October 9, 2025, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions, resulting in a decrease in the number of shares of Common Stock beneficially owned by the Reporting Persons by more than one percent of the outstanding shares of Common Stock of the Issuer. 1. 75,262 shares on October 8, 2025, at a weighted average per share sale price of $33.8651. 2. 48,884 shares on October 9, 2025, at a weighted average per share sale price of $32.068.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in rows 7, 8, 9, 10, 11 and 13 on each of the cover pages of this Amendment No. 6 to the Schedule 13D, and the information set forth or incorporated in Items 2, 3, 4, 6 and 7, is incorporated by reference in its entirety into this Item 5.
(b)	Regarding the number of shares as to which such person has: (i) sole power to vote or to direct the vote: See line 7 of cover sheets, (ii) shared power to vote or to direct the vote: See line 8 of cover sheets, (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets, and (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets.
(c)	During the past 60 days, Reprogrammed Interchange LLC sold the following shares of Vor Biopharma Inc. in open market transactions. Each share amount and weighted average per share sale price from August 25, 2005 through September 16, 2025 reflects the 1-for-20 reverse stock split of Vor Biopharma Inc. Common Stock effected September 18, 2025. 1. 19,367 shares on August 25, 2025, at a weighted average per share sale price of $42,3256. 2. 14,209 shares on August 26, 2025, at a weighted average per share sale price of $41.6165. 3. 30,582 shares on August 27, 2025, at a weighted average per share sale price of $40.1057. 4. 40,317 shares on August 28, 2025, at a weighted average per share sale price of $40.2307. 5. 27,730 shares on September 3, 2025, at a weighted average per share sale price of $39.9222. 6. 22,650 shares on September 4, 2025, at a weighted average per share sale price of $38.5709. 7. 20,000 shares on September 5, 2025, at a weighted average per share sale price of $39.3639. 8. 23,221 shares on September 8, 2025, at a weighted average per share sale price of $39.7949. 9. 22,461 shares on September 9, 2025, at a weighted average per share sale price of $40,0084. 10. 17,500 shares on September 10, 2025, at a weighted average per share sale price of $36.3019. 11. 14,240 shares on September 11, 2025, at a weighted average per share sale price of $36.6151. 12. 15,000 shares on September 12, 2025, at a weighted average per share sale price of $35.0811. 13. 20,000 shares on September 15, 2025, at a weighted average per share sale price of $32.815. 14. 22,363 shares on September 16, 2025, at a weighted average per share sale price of $30.8023. 15. 1,400 shares on October 1, 2025, at a weighted average per share sale price of $39.1925. 16. 32,451 shares on October 2, 2025, at a weighted average per share sale price of $39.828. 17. 7,901 shares on October 3, 2025, at a weighted average per share sale price of $37.832. 18. 70,763 shares on October 6, 2025, at a weighted average per share sale price of $37.0079. 19. 27,624 shares on October 7, 2025, at a weighted average per share sale price of $33.8369.
(d)	Not applicable.
(e)	Not applicable.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Reprogrammed Interchange LLC

Signature:	/s/ Frank Huang
Name/Title:	Frank Huang, Manager
Date:	10/10/2025

Reid Hoffman

Signature:	/s/ Reid Hoffman
Name/Title:	Reid Hoffman
Date:	10/10/2025

FAQ

What stake do Reid Hoffman and Reprogrammed Interchange LLC hold in Vor Biopharma (VOR)?

They beneficially own 1,374,775 shares, representing 20.1% of Vor Biopharma's common stock.

When were the most recent sales executed by the reporting persons?

The filing shows sales on October 8, 2025 (75,262 shares at $33.8651) and October 9, 2025 (48,884 shares at $32.068), among earlier trades.

Do the reporting persons retain voting control over these shares?

The cover pages report 0 sole voting power and 1,374,775 shares of shared voting power, indicating shared control rather than sole control.

Were any contracts or understandings with the issuer disclosed?

No. Item 6 states that there are no contracts, arrangements or understandings with respect to the issuer's securities.

Did the filing reflect any corporate actions that affect share counts?

Yes. All share amounts reflect a 1-for-20 reverse stock split effected on September 18, 2025 as noted in Item 5.